You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAlogliptin
Accession NumberDB06203
TypeSmall Molecule
GroupsApproved
DescriptionAlogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Structure
Thumb
Synonyms
Alogliptina
Alogliptine
Alogliptinum
SYR-322
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alogliptintablet, film coated12.5 mg/1oralPerrigo New York Inc2016-04-08Not applicableUs
Alogliptintablet, film coated25 mg/1oralPerrigo New York Inc2016-04-08Not applicableUs
Alogliptintablet, film coated6.25 mg/1oralPerrigo New York Inc2016-04-08Not applicableUs
Nesinatablet6.25 mgoralTakeda Canada Inc2014-04-30Not applicableCanada
Nesinatablet, film coated25 mg/1oralTakeda Pharmaceuticals America, Inc.2013-01-25Not applicableUs
Nesinatablet12.5 mgoralTakeda Canada Inc2014-04-30Not applicableCanada
Nesinatablet, film coated6.25 mg/1oralTakeda Pharmaceuticals America, Inc.2013-01-25Not applicableUs
Nesinatablet25 mgoralTakeda Canada Inc2014-05-13Not applicableCanada
Nesinatablet, film coated12.5 mg/1oralTakeda Pharmaceuticals America, Inc.2013-01-25Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Alogliptin and Metformin HydrochloridePerrigo New York Inc
Alogliptin and PioglitazonePerrigo New York Inc
KazanoTakeda Canada Inc
OseniTakeda Canada Inc
Salts
Name/CASStructureProperties
Alogliptin Benzoate
Thumb
  • InChI Key: KEJICOXJTRHYAK-XFULWGLBSA-N
  • Monoisotopic Mass: 461.206304377
  • Average Mass: 461.513
DBSALT000007
Categories
UNIIJHC049LO86
CAS number850649-61-5
WeightAverage: 339.3916
Monoisotopic: 339.169524941
Chemical FormulaC18H21N5O2
InChI KeyInChIKey=ZSBOMTDTBDDKMP-OAHLLOKOSA-N
InChI
InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
IUPAC Name
2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile
SMILES
CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylmethylamines
Direct ParentPhenylmethylamines
Alternative Parents
Substituents
  • Dialkylarylamine
  • Phenylmethylamine
  • Benzonitrile
  • Pyrimidone
  • Aminopyrimidine
  • 3-aminopiperidine
  • Pyrimidine
  • Piperidine
  • Hydropyrimidine
  • Heteroaromatic compound
  • Vinylogous amide
  • Urea
  • Tertiary amine
  • Lactam
  • Azacycle
  • Organoheterocyclic compound
  • Nitrile
  • Carbonitrile
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
PharmacodynamicsPeak inhibition of DPP-4 occurs within 2-3 hours after a single-dose administration to healthy subjects. The peak inhibition of DPP-4 exceeded 93% across doses of 12.5 mg to 800 mg. Inhibition of DPP-4 remained above 80% at 24 hours for doses greater than or equal to 25 mg. Alogliptin also demonstrated decreases in postprandial glucagon while increasing postprandial active GLP-1 levels compared to placebo over an 8-hour period following a standardized meal. Alogliptin does not affect the QTc interval.
Mechanism of actionAlogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 ( GLP-1). The inhibition of DPP-4 increases the amount of active plasma incretins which helps with glycemic control. GIP and GLP-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. GLP-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying.
Related Articles
AbsorptionThe pharmacokinetics of NESINA was also shown to be similar in healthy subjects and in patients with type 2 diabetes. When single, oral doses up to 800 mg in healthy subjects and type 2 diabetes patients are given, the peak plasma alogliptin concentration (median Tmax) occurred 1 to 2 hours after dosing. Accumulation of aloglipin is minimal. The absolute bioavailability of NESINA is approximately 100%. Food does not affect the absorption of alogliptin.
Volume of distribution

Following a single, 12.5 mg intravenous infusion of alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L, indicating that the drug is well distributed into tissues.

Protein bindingAlogliptin is 20% bound to plasma proteins.
Metabolism

Alogliptin does not undergo extensive metabolism. Two minor metabolites that were detected are N-demethylated alogliptin (<1% of parent compound) and N-acetylated alogliptin (<6% of parent compound). The N-demethylated metabolite is active and an inhibitor of DPP-4. The N-acetylated metabolite is inactive. Cytochrome enzymes that are involved with the metabolism of alogliptin are CYP2D6 and CYP3A4 but the extent to which this occurs is minimal. Approximately 10-20% of the dose is hepatically metabolized by cytochrome enzymes.

Route of eliminationRenal excretion (76%) and feces (13%). 60% to 71% of the dose is excreted as unchanged drug in the urine.
Half lifeTerminal half-life = 21 hours
Clearance

Renal clearance = 9.6 L/h (this value indicates some active renal tubular secretion);
Systemic clearance = 14.0 L/h.

ToxicityCommon adverse reactions (reported in ≥4% of patients treated with alogliptin 25 mg and more frequently than in patients who received placebo) are: nasopharyngitis, headache, and upper respiratory tract infection.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9942
Blood Brain Barrier+0.9738
Caco-2 permeable-0.5492
P-glycoprotein substrateSubstrate0.6453
P-glycoprotein inhibitor INon-inhibitor0.6811
P-glycoprotein inhibitor IINon-inhibitor0.9238
Renal organic cation transporterNon-inhibitor0.591
CYP450 2C9 substrateNon-substrate0.8003
CYP450 2D6 substrateNon-substrate0.7259
CYP450 3A4 substrateSubstrate0.5528
CYP450 1A2 substrateNon-inhibitor0.9169
CYP450 2C9 inhibitorNon-inhibitor0.8475
CYP450 2D6 inhibitorNon-inhibitor0.9038
CYP450 2C19 inhibitorNon-inhibitor0.8527
CYP450 3A4 inhibitorNon-inhibitor0.7608
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9363
Ames testNon AMES toxic0.5595
CarcinogenicityNon-carcinogens0.8887
BiodegradationNot ready biodegradable0.9931
Rat acute toxicity2.5603 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5507
hERG inhibition (predictor II)Inhibitor0.8389
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral12.5 mg
Tabletoral25 mg
Tabletoral6.25 mg
Tablet, film coatedoral12.5 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral6.25 mg/1
Tabletoral
Tablet, film coatedoral
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5965584 No1996-06-192016-06-19Us
US6150383 No1996-06-192016-06-19Us
US6150384 No1996-06-192016-06-19Us
US6166042 No1996-06-192016-06-19Us
US6166043 No1996-06-192016-06-19Us
US6172090 No1996-06-192016-06-19Us
US6211205 No1996-06-192016-06-19Us
US6271243 No1996-06-192016-06-19Us
US6303640 No1996-08-092016-08-09Us
US6303661 No1997-04-242017-04-24Us
US6329404 No1996-06-192016-06-19Us
US6890898 No1999-02-022019-02-02Us
US7078381 No1999-02-022019-02-02Us
US7459428 No1999-02-022019-02-02Us
US7807689 No2008-06-272028-06-27Us
US8173663 No2005-03-152025-03-15Us
US8288539 No2005-03-152025-03-15Us
US8637079 No2009-06-042029-06-04Us
US8697125 No2009-01-222029-01-22Us
US8900638 No2009-05-242029-05-24Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySparingly soluble FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.58 mg/mLALOGPS
logP0.66ALOGPS
logP1.16ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)9.47ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area93.67 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity104.26 m3·mol-1ChemAxon
Polarizability35.44 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Kenji Nakamura, Kenichiro Kiyoshima, Junya Nomura, “SOLID PREPARATION COMPRISING ALOGLIPTIN AND PIOGLITAZONE.” U.S. Patent US20100092551, issued April 15, 2010.

US20100092551
General References
  1. Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008 Mar;30(3):513-27. doi: 10.1016/j.clinthera.2008.03.005. [PubMed:18405789 ]
  2. Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008 Mar;30(3):499-512. doi: 10.1016/j.clinthera.2008.03.004. [PubMed:18405788 ]
  3. Golightly LK, Drayna CC, McDermott MT: Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012 Aug 1;51(8):501-14. doi: 10.2165/11632930-000000000-00000. [PubMed:22686547 ]
External Links
ATC CodesA10BD13A10BD09A10BH04
AHFS Codes
  • 68:20.05
PDB EntriesNot Available
FDA labelDownload (648 KB)
MSDSDownload (479 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Alogliptin.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Alogliptin.
AbirateroneThe metabolism of Alogliptin can be decreased when combined with Abiraterone.
AcetohexamideAlogliptin may increase the hypoglycemic activities of Acetohexamide.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Alogliptin.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Alogliptin.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Alogliptin.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Alogliptin.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Alogliptin.
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Alogliptin.
AmiodaroneThe metabolism of Alogliptin can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Alogliptin.
AmoxapineAmoxapine may increase the hypoglycemic activities of Alogliptin.
AprepitantThe serum concentration of Alogliptin can be increased when it is combined with Aprepitant.
AripiprazoleThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Aripiprazole.
Arsenic trioxideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Arsenic trioxide.
ArtemetherThe metabolism of Alogliptin can be decreased when combined with Artemether.
ArticaineThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Articaine.
AsenapineThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Asenapine.
AtazanavirThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Atazanavir.
AtomoxetineThe metabolism of Alogliptin can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Alogliptin.
BenazeprilThe risk or severity of adverse effects can be increased when Alogliptin is combined with Benazepril.
BendroflumethiazideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypoglycemic activities of Alogliptin.
BetamethasoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Betamethasone.
BetaxololThe metabolism of Alogliptin can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Alogliptin can be decreased when it is combined with Bexarotene.
BoceprevirThe serum concentration of Alogliptin can be decreased when it is combined with Boceprevir.
BortezomibThe metabolism of Alogliptin can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Alogliptin can be decreased when it is combined with Bosentan.
BrexpiprazoleThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Brexpiprazole.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Alogliptin.
BumetanideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Bumetanide.
BupropionThe metabolism of Alogliptin can be decreased when combined with Bupropion.
BuserelinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Buserelin.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Alogliptin.
CandoxatrilThe risk or severity of adverse effects can be increased when Alogliptin is combined with Candoxatril.
CaptoprilThe risk or severity of adverse effects can be increased when Alogliptin is combined with Captopril.
CarbamazepineThe metabolism of Alogliptin can be increased when combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypoglycemic activities of Alogliptin.
CelecoxibThe metabolism of Alogliptin can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Alogliptin can be increased when it is combined with Ceritinib.
ChloroquineThe metabolism of Alogliptin can be decreased when combined with Chloroquine.
ChlorothiazideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Chlorothiazide.
ChlorpromazineThe metabolism of Alogliptin can be decreased when combined with Chlorpromazine.
ChlorpropamideAlogliptin may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Chlorthalidone.
CholecalciferolThe metabolism of Alogliptin can be decreased when combined with Cholecalciferol.
CilazaprilThe risk or severity of adverse effects can be increased when Alogliptin is combined with Cilazapril.
CimetidineThe metabolism of Alogliptin can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Alogliptin can be decreased when combined with Cinacalcet.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Alogliptin.
CitalopramCitalopram may increase the hypoglycemic activities of Alogliptin.
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Alogliptin.
ClarithromycinThe metabolism of Alogliptin can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Alogliptin can be decreased when combined with Clemastine.
ClobazamThe metabolism of Alogliptin can be decreased when combined with Clobazam.
ClomipramineClomipramine may increase the hypoglycemic activities of Alogliptin.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Alogliptin.
ClotrimazoleThe metabolism of Alogliptin can be decreased when combined with Clotrimazole.
ClozapineThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Clozapine.
CobicistatThe serum concentration of Alogliptin can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Alogliptin can be decreased when combined with Cocaine.
ConivaptanThe serum concentration of Alogliptin can be increased when it is combined with Conivaptan.
CorticotropinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Corticotropin.
Cortisone acetateThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Cortisone acetate.
CrizotinibThe metabolism of Alogliptin can be decreased when combined with Crizotinib.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Alogliptin.
CyclophosphamideThe risk or severity of adverse effects can be increased when Alogliptin is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Alogliptin.
CyclosporineThe metabolism of Alogliptin can be decreased when combined with Cyclosporine.
Cyproterone acetateThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Cyproterone acetate.
DabrafenibThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Dabrafenib.
DanazolThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Danazol.
DapoxetineDapoxetine may increase the hypoglycemic activities of Alogliptin.
DarifenacinThe metabolism of Alogliptin can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Alogliptin can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Alogliptin can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Alogliptin can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Alogliptin.
DelavirdineThe metabolism of Alogliptin can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Alogliptin.
DesipramineThe metabolism of Alogliptin can be decreased when combined with Desipramine.
DesogestrelThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Desogestrel.
DexamethasoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Dexamethasone.
DiazoxideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Diazoxide.
DienogestThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Dienogest.
DiflunisalDiflunisal may increase the hypoglycemic activities of Alogliptin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Alogliptin.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Alogliptin.
DihydroergotamineThe metabolism of Alogliptin can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Alogliptin.
DiltiazemThe metabolism of Alogliptin can be decreased when combined with Diltiazem.
DiphenhydramineThe metabolism of Alogliptin can be decreased when combined with Diphenhydramine.
DisopyramideAlogliptin may increase the hypoglycemic activities of Disopyramide.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Alogliptin.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Alogliptin.
DoxycyclineThe metabolism of Alogliptin can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Alogliptin can be decreased when combined with Dronedarone.
DrospirenoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Drospirenone.
DuloxetineThe metabolism of Alogliptin can be decreased when combined with Duloxetine.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Alogliptin.
EfavirenzThe serum concentration of Alogliptin can be decreased when it is combined with Efavirenz.
EliglustatThe metabolism of Alogliptin can be decreased when combined with Eliglustat.
EnalaprilThe risk or severity of adverse effects can be increased when Alogliptin is combined with Enalapril.
EnalaprilatThe risk or severity of adverse effects can be increased when Alogliptin is combined with Enalaprilat.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Alogliptin.
EnzalutamideThe serum concentration of Alogliptin can be decreased when it is combined with Enzalutamide.
EpinephrineThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Epinephrine.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Alogliptin.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Alogliptin.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Alogliptin.
ErythromycinThe metabolism of Alogliptin can be decreased when combined with Erythromycin.
EscitalopramEscitalopram may increase the hypoglycemic activities of Alogliptin.
Eslicarbazepine acetateThe serum concentration of Alogliptin can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Alogliptin.
EstradiolThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Estradiol.
Estrone sulfateThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Estrone sulfate.
Etacrynic acidThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Etacrynic acid.
Ethinyl EstradiolThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Ethinyl Estradiol.
Ethynodiol diacetateThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Ethynodiol diacetate.
EtonogestrelThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Etonogestrel.
EtoperidoneEtoperidone may increase the hypoglycemic activities of Alogliptin.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Alogliptin.
EverolimusThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Everolimus.
FenfluramineFenfluramine may increase the hypoglycemic activities of Alogliptin.
FluconazoleThe metabolism of Alogliptin can be decreased when combined with Fluconazole.
FludrocortisoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Fludrocortisone.
FluoxetineFluoxetine may increase the hypoglycemic activities of Alogliptin.
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Alogliptin.
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Alogliptin.
FosamprenavirThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Fosamprenavir.
FosaprepitantThe serum concentration of Alogliptin can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Alogliptin is combined with Fosinopril.
FosphenytoinThe metabolism of Alogliptin can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypoglycemic activities of Alogliptin.
FurosemideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Furosemide.
Fusidic AcidThe serum concentration of Alogliptin can be increased when it is combined with Fusidic Acid.
GarlicThe serum concentration of Alogliptin can be decreased when it is combined with Garlic.
GlibornurideAlogliptin may increase the hypoglycemic activities of Glibornuride.
GliclazideAlogliptin may increase the hypoglycemic activities of Gliclazide.
GlimepirideAlogliptin may increase the hypoglycemic activities of Glimepiride.
GlipizideAlogliptin may increase the hypoglycemic activities of Glipizide.
GliquidoneAlogliptin may increase the hypoglycemic activities of Gliquidone.
GlisoxepideAlogliptin may increase the hypoglycemic activities of Glisoxepide.
GlyburideAlogliptin may increase the hypoglycemic activities of Glyburide.
GoserelinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Goserelin.
HaloperidolThe metabolism of Alogliptin can be decreased when combined with Haloperidol.
HistrelinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Histrelin.
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Alogliptin.
HydrochlorothiazideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydrochlorothiazide.
HydrocortisoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydrocortisone.
HydroflumethiazideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydroflumethiazide.
Hydroxyprogesterone caproateThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydroxyprogesterone caproate.
IdelalisibThe serum concentration of Alogliptin can be increased when it is combined with Idelalisib.
IloperidoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Iloperidone.
ImatinibThe metabolism of Alogliptin can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Alogliptin.
ImipramineThe metabolism of Alogliptin can be decreased when combined with Imipramine.
IndalpineIndalpine may increase the hypoglycemic activities of Alogliptin.
IndapamideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Indapamide.
IndinavirThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Indinavir.
Insulin AspartAlogliptin may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirAlogliptin may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineAlogliptin may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineAlogliptin may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanAlogliptin may increase the hypoglycemic activities of Insulin Human.
Insulin LisproAlogliptin may increase the hypoglycemic activities of Insulin Lispro.
Insulin PorkAlogliptin may increase the hypoglycemic activities of Insulin Pork.
IproclozideIproclozide may increase the hypoglycemic activities of Alogliptin.
IproniazidIproniazid may increase the hypoglycemic activities of Alogliptin.
IsavuconazoniumThe metabolism of Alogliptin can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Alogliptin.
IsoniazidThe metabolism of Alogliptin can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Alogliptin can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Alogliptin can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Alogliptin can be increased when it is combined with Ivacaftor.
KetoconazoleThe metabolism of Alogliptin can be decreased when combined with Ketoconazole.
LanreotideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Lanreotide.
LanreotideAlogliptin may increase the hypoglycemic activities of Lanreotide.
LeuprolideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Leuprolide.
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Alogliptin.
LevonorgestrelThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Levonorgestrel.
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Alogliptin.
LisinoprilThe risk or severity of adverse effects can be increased when Alogliptin is combined with Lisinopril.
LopinavirThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Lopinavir.
LorcaserinThe metabolism of Alogliptin can be decreased when combined with Lorcaserin.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Alogliptin.
LovastatinThe metabolism of Alogliptin can be decreased when combined with Lovastatin.
Lu AA21004Lu AA21004 may increase the hypoglycemic activities of Alogliptin.
LuliconazoleThe serum concentration of Alogliptin can be increased when it is combined with Luliconazole.
LumefantrineThe metabolism of Alogliptin can be decreased when combined with Lumefantrine.
LurasidoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Lurasidone.
MebanazineMebanazine may increase the hypoglycemic activities of Alogliptin.
MecaserminAlogliptin may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone acetateThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Medroxyprogesterone acetate.
Megestrol acetateThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Megestrol acetate.
MesalazineMesalazine may increase the hypoglycemic activities of Alogliptin.
MestranolThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Mestranol.
MethadoneThe metabolism of Alogliptin can be decreased when combined with Methadone.
MethotrimeprazineThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Methotrimeprazine.
MethyclothiazideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Methyclothiazide.
Methylene blueMethylene blue may increase the hypoglycemic activities of Alogliptin.
MethylprednisoloneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Methylprednisolone.
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Alogliptin.
MetolazoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Metolazone.
MetoprololThe metabolism of Alogliptin can be decreased when combined with Metoprolol.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Alogliptin.
MifepristoneAlogliptin may increase the hypoglycemic activities of Mifepristone.
MifepristoneThe metabolism of Alogliptin can be decreased when combined with Mifepristone.
MilnacipranMilnacipran may increase the hypoglycemic activities of Alogliptin.
MinaprineMinaprine may increase the hypoglycemic activities of Alogliptin.
MirabegronThe metabolism of Alogliptin can be decreased when combined with Mirabegron.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Alogliptin.
MitotaneThe serum concentration of Alogliptin can be decreased when it is combined with Mitotane.
MoclobemideMoclobemide may increase the hypoglycemic activities of Alogliptin.
ModafinilThe serum concentration of Alogliptin can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Alogliptin is combined with Moexipril.
NafcillinThe serum concentration of Alogliptin can be decreased when it is combined with Nafcillin.
NateglinideAlogliptin may increase the hypoglycemic activities of Nateglinide.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Alogliptin.
NefazodoneThe metabolism of Alogliptin can be decreased when combined with Nefazodone.
NelfinavirThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Nelfinavir.
NetupitantThe serum concentration of Alogliptin can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Alogliptin can be decreased when combined with Nevirapine.
NiacinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Niacin.
NialamideNialamide may increase the hypoglycemic activities of Alogliptin.
NicardipineThe metabolism of Alogliptin can be decreased when combined with Nicardipine.
NilotinibThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Nilotinib.
NorethisteroneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Norethisterone.
NorgestimateThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Norgestimate.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Alogliptin.
OctamoxinOctamoxin may increase the hypoglycemic activities of Alogliptin.
OctreotideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Octreotide.
OctreotideAlogliptin may increase the hypoglycemic activities of Octreotide.
OlanzapineOlanzapine may increase the hypoglycemic activities of Alogliptin.
OlaparibThe metabolism of Alogliptin can be decreased when combined with Olaparib.
OmapatrilatThe risk or severity of adverse effects can be increased when Alogliptin is combined with Omapatrilat.
OsimertinibThe serum concentration of Alogliptin can be increased when it is combined with Osimertinib.
OxandroloneOxandrolone may increase the hypoglycemic activities of Alogliptin.
OxymetholoneOxymetholone may increase the hypoglycemic activities of Alogliptin.
PalbociclibThe serum concentration of Alogliptin can be increased when it is combined with Palbociclib.
PaliperidoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Paliperidone.
PanobinostatThe metabolism of Alogliptin can be decreased when combined with Panobinostat.
PargylinePargyline may increase the hypoglycemic activities of Alogliptin.
ParoxetineParoxetine may increase the hypoglycemic activities of Alogliptin.
PasireotideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Pasireotide.
PasireotideAlogliptin may increase the hypoglycemic activities of Pasireotide.
Peginterferon alfa-2bThe serum concentration of Alogliptin can be decreased when it is combined with Peginterferon alfa-2b.
PegvisomantPegvisomant may increase the hypoglycemic activities of Alogliptin.
PentamidineThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Pentamidine.
PentamidineAlogliptin may increase the hypoglycemic activities of Pentamidine.
PentobarbitalThe metabolism of Alogliptin can be increased when combined with Pentobarbital.
PerindoprilThe risk or severity of adverse effects can be increased when Alogliptin is combined with Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Alogliptin is combined with Pethidine.
PhenelzinePhenelzine may increase the hypoglycemic activities of Alogliptin.
PheniprazinePheniprazine may increase the hypoglycemic activities of Alogliptin.
PhenobarbitalThe metabolism of Alogliptin can be increased when combined with Phenobarbital.
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Alogliptin.
PhenytoinThe metabolism of Alogliptin can be increased when combined with Phenytoin.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Alogliptin.
PiperazineThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Piperazine.
PipotiazineThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Pipotiazine.
PirlindolePirlindole may increase the hypoglycemic activities of Alogliptin.
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Alogliptin.
PolythiazideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Polythiazide.
PosaconazoleThe metabolism of Alogliptin can be decreased when combined with Posaconazole.
PrednisoloneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Prednisolone.
PrednisoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Prednisone.
PrimidoneThe metabolism of Alogliptin can be increased when combined with Primidone.
ProgesteroneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Progesterone.
PromazineThe metabolism of Alogliptin can be decreased when combined with Promazine.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Alogliptin.
QuetiapineThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Quetiapine.
QuinaprilThe risk or severity of adverse effects can be increased when Alogliptin is combined with Quinapril.
QuinethazoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Quinethazone.
QuinidineThe metabolism of Alogliptin can be decreased when combined with Quinidine.
QuinineAlogliptin may increase the hypoglycemic activities of Quinine.
QuinineThe metabolism of Alogliptin can be decreased when combined with Quinine.
RamiprilThe risk or severity of adverse effects can be increased when Alogliptin is combined with Ramipril.
RanolazineThe metabolism of Alogliptin can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the hypoglycemic activities of Alogliptin.
RepaglinideAlogliptin may increase the hypoglycemic activities of Repaglinide.
RescinnamineThe risk or severity of adverse effects can be increased when Alogliptin is combined with Rescinnamine.
RifabutinThe metabolism of Alogliptin can be increased when combined with Rifabutin.
RifampicinThe metabolism of Alogliptin can be increased when combined with Rifampicin.
RifapentineThe metabolism of Alogliptin can be increased when combined with Rifapentine.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Alogliptin.
RisperidoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Risperidone.
RitonavirThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Ritonavir.
RolapitantThe metabolism of Alogliptin can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Alogliptin can be decreased when combined with Ropinirole.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Alogliptin.
SafrazineSafrazine may increase the hypoglycemic activities of Alogliptin.
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Alogliptin.
SaquinavirThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Saquinavir.
SelegilineSelegiline may increase the hypoglycemic activities of Alogliptin.
SertralineSertraline may increase the hypoglycemic activities of Alogliptin.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Alogliptin.
SildenafilThe metabolism of Alogliptin can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Alogliptin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Alogliptin can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Alogliptin.
SirolimusThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Sirolimus.
SpiraprilThe risk or severity of adverse effects can be increased when Alogliptin is combined with Spirapril.
St. John's WortThe metabolism of Alogliptin can be increased when combined with St. John&#39;s Wort.
StanozololStanozolol may increase the hypoglycemic activities of Alogliptin.
StiripentolThe serum concentration of Alogliptin can be increased when it is combined with Stiripentol.
SulfadiazineAlogliptin may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleAlogliptin may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleAlogliptin may increase the hypoglycemic activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Alogliptin can be decreased when combined with Sulfisoxazole.
SunitinibAlogliptin may increase the hypoglycemic activities of Sunitinib.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Alogliptin.
TacrolimusThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Tacrolimus.
TelaprevirThe metabolism of Alogliptin can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Alogliptin can be decreased when combined with Telithromycin.
TemocaprilThe risk or severity of adverse effects can be increased when Alogliptin is combined with Temocapril.
TemsirolimusThe risk or severity of adverse effects can be increased when Alogliptin is combined with Temsirolimus.
TemsirolimusThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Temsirolimus.
TerbinafineThe metabolism of Alogliptin can be decreased when combined with Terbinafine.
TestosteroneTestosterone may increase the hypoglycemic activities of Alogliptin.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Alogliptin.
ThioridazineThe metabolism of Alogliptin can be decreased when combined with Thioridazine.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Alogliptin.
TiclopidineThe metabolism of Alogliptin can be decreased when combined with Ticlopidine.
TipranavirThe serum concentration of Alogliptin can be decreased when it is combined with Tipranavir.
TocilizumabThe serum concentration of Alogliptin can be decreased when it is combined with Tocilizumab.
TolazamideAlogliptin may increase the hypoglycemic activities of Tolazamide.
TolbutamideAlogliptin may increase the hypoglycemic activities of Tolbutamide.
ToloxatoneToloxatone may increase the hypoglycemic activities of Alogliptin.
TorasemideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Alogliptin is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Alogliptin.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Alogliptin.
TrazodoneTrazodone may increase the hypoglycemic activities of Alogliptin.
TriamcinoloneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Triamcinolone.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Alogliptin.
TrichlormethiazideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Trichlormethiazide.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Alogliptin.
TriptorelinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Triptorelin.
VenlafaxineThe metabolism of Alogliptin can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Alogliptin can be decreased when combined with Verapamil.
VilazodoneVilazodone may increase the hypoglycemic activities of Alogliptin.
VoriconazoleThe metabolism of Alogliptin can be decreased when combined with Voriconazole.
VorinostatThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Vorinostat.
VortioxetineVortioxetine may increase the hypoglycemic activities of Alogliptin.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Alogliptin.
ZimelidineZimelidine may increase the hypoglycemic activities of Alogliptin.
ZiprasidoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Virus receptor activity
Specific Function:
Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Its interaction with ADA also ...
Gene Name:
DPP4
Uniprot ID:
P27487
Molecular Weight:
88277.935 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:17 / Updated on September 30, 2016 02:27